Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
47.77
-0.27 (-0.56%)
Jun 27, 2025, 4:00 PM - Market closed
Qiagen Revenue
Qiagen had revenue of $483.46M in the quarter ending March 31, 2025, with 5.37% growth. This brings the company's revenue in the last twelve months to $2.00B, up 3.31% year-over-year. In the year 2024, Qiagen had annual revenue of $1.98B with 0.66% growth.
Revenue (ttm)
$2.00B
Revenue Growth
+3.31%
P/S Ratio
5.17
Revenue / Employee
$335,658
Employees
5,967
Market Cap
10.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
QGEN News
- 1 day ago - QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board - Business Wire
- 9 days ago - Qiagen and Gencurix Enter Clinical Diagnostics Partnership - Market Watch
- 9 days ago - QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - Business Wire
- 13 days ago - QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Business Wire
- 22 days ago - Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors - Business Wire
- 25 days ago - QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
- 25 days ago - Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - PRNewsWire
- 5 weeks ago - QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions - Business Wire